Story · Medicine & Biotech

Audit of Appropriate Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients With Type 2 Diabetes Mellitus and Heart Failure or Chronic Kidney Disease

1 outlet · first reported by Cureus 1d ago

Coverage, in order

  1. 1d ago
    Cureus indie study
    Audit of Appropriate Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Use in Patients With Type 2 Diabetes Mellitus and Heart Failure or Chronic Kidney Disease

    Background Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide important cardiovascular and renal benefits in patients with type 2 diabetes mellitus (T2DM), particularly those with heart failure (HF) and/or chronic kidney disease (CKD). Despite guideline recommendations, their use may remain…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.